How Clinicians Evaluate PML Risk in Tysabri Patients

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

From General Health Information to Targeted Risk Awareness

If you or a loved one is taking Tysabri and experiencing new neurological symptoms, understanding how clinicians evaluate the risk of PML is critical. Building on decades of research into biologic therapies and their rare adverse effects, this page explains the diagnostic approach, monitoring protocols, and what questions patients should ask their healthcare provider.

Medical Evidence Linking Tysabri to PML

Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis (MS) and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus. For patients in Massachusetts who have developed PML after Tysabri treatment, understanding the medical evidence and legal considerations—including the statute of limitations—is essential. PML is an opportunistic viral infection of the brain that typically occurs only in immunocompromised individuals and usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The U.S. Food and Drug Administration (FDA) has issued a boxed warning stating that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Three key risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals are instructed to monitor patients for any new signs or symptoms suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as cognitive impairment, motor weakness, gait disturbance, and visual changes. These symptoms overlap with those of multiple sclerosis, which can delay diagnosis. The FDA Adverse Event Reporting System (FAERS) lists fatigue, multiple sclerosis relapse, headache, gait disturbance, memory impairment, and balance disorder among the most frequently reported adverse events associated with Tysabri (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not confirm causation, they highlight the range of neurological symptoms that may be observed in Tysabri-treated patients.

Mechanistic Pathways and Adequacy of Warnings

Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration into the central nervous system. This mechanism reduces inflammation in MS but also impairs immune surveillance in the brain. The JC virus, which is latent in most people, can reactivate and cause PML when immune control is compromised. Tysabri’s effect on immune cell trafficking is believed to create an environment permissive for JC virus replication and PML development. The boxed warning explicitly states that Tysabri increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA-approved labeling for Tysabri includes a boxed warning that clearly describes the risk of PML and the identified risk factors (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label also notes that Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program, which is designed to mitigate risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, questions may arise about whether prescribers adequately communicated these risks to patients and whether monitoring protocols were followed. For patients who developed PML, the adequacy of warnings and the timing of diagnosis are critical factors.

Legal Considerations and Statute of Limitations in Massachusetts

For individuals in Massachusetts who have been harmed by Tysabri-associated PML, legal options may include filing a product liability or medical malpractice claim. The statute of limitations for such claims in Massachusetts is generally three years from the date the injury was discovered or should have been discovered. This means that the clock starts ticking when the patient or their family becomes aware of the link between Tysabri and the PML diagnosis. Given that PML symptoms can mimic MS progression, the date of discovery may be later than the actual onset of symptoms. It is important to consult with an attorney experienced in pharmaceutical litigation to determine the applicable deadline. The risk of PML increases with longer Tysabri treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, PML can occur at any time during treatment. The latency period between JC virus reactivation and clinical symptoms is not precisely defined, but once symptoms appear, the disease can progress rapidly. Early diagnosis and discontinuation of Tysabri are critical, as the boxed warning advises withholding the drug immediately at the first sign suggestive of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Delays in diagnosis can worsen outcomes.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri-related PML claims in Massachusetts?

In Massachusetts, the statute of limitations for product liability or medical malpractice claims is generally three years from the date the injury was discovered or should have been discovered. For Tysabri-associated PML, this means the clock starts when the patient or family becomes aware of the link between the drug and the PML diagnosis. Given that PML symptoms can mimic MS progression, the discovery date may be later than symptom onset. It is crucial to consult an attorney promptly to preserve your right to file a claim.

What medical evidence links Tysabri to PML?

Tysabri carries a boxed warning from the FDA stating it increases the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Key risk factors include anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. PML is a severe brain infection caused by JC virus reactivation, often leading to death or disability. The FDA Adverse Event Reporting System lists neurological symptoms such as fatigue, gait disturbance, and memory impairment among reported events (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.